Manyi Xu

机构：Beijing Chest Hospital · ORCID：0000-0002-6937-3652

发表论文 30 篇 · 总被引 236 次 · h-index 9

代表论文

Discovery of Novel Celastrol–Imidazole Derivatives with Anticancer Activity In Vitro and In Vivo (2022 · Journal of Medicinal Chemistry · 被引 25)
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer (2023 · Investigational New Drugs · 被引 12)
Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer (2023 · Journal of Thoracic Disease · 被引 12)
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer (2023 · Journal of Cancer Research and Clinical Oncology · 被引 10)
Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma (2023 · Journal of Thoracic Disease · 被引 10)
Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases (2024 · Clinical & Translational Oncology · 被引 7)